AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025)
AVITA Medical's (RCEL) quarterly Cash from Financing Activities came in at $248000.0 in Q4 2025, down 75.71% YoY from $1.0 million in Q4 2024, and down 98.2% on a QoQ basis from $13.8 million in Q3 2025.
AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025) Analysis & Trends
AVITA Medical (RCEL) has 7 years of Cash from Financing Activities data on file, last reported at $248000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 75.71% year-over-year to $248000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.9 million (up 325.77% YoY) and the FY2025 annual result came in at $14.9 million, up 325.77% from the prior year.
- Cash from Financing Activities slipped to $248000.0 in Q4 2025, from $13.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $64.1 million in Q3 2021 to a low of -$64.1 million in Q4 2022.
- A 5-year average of $2.6 million and a median of $579500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 1601625.0% — and 2022, when it sank 397.95%.
- Tracing RCEL's Cash from Financing Activities over 5 years: stood at $64.1 million in 2021, then slumped by 200.0% to -$64.1 million in 2022, then soared by 161.55% to $39.4 million in 2023, then slumped by 97.41% to $1.0 million in 2024, then sank by 75.71% to $248000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $248000.0 (Q4 2025), $13.8 million (Q3 2025), and $559000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -213.50 Mn |
| 10 | AVITA Medical | 311.65 Mn | 300.52 Mn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 248,000.00 |
| Dec 31, 2025 | 248,000.00 |
| Sep 30, 2025 | 13.77 Mn |
| Sep 30, 2025 | 13.77 Mn |
| Jun 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 559,000.00 |
| Mar 31, 2025 | 363,000.00 |
| Mar 31, 2025 | 363,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 849,000.00 |
| Jun 30, 2024 | 849,000.00 |
| Mar 31, 2024 | 631,000.00 |
| Mar 31, 2024 | 631,000.00 |
| Dec 31, 2023 | 39.43 Mn |
| Dec 31, 2023 | 39.43 Mn |
| Sep 30, 2023 | 600,000.00 |
| Sep 30, 2023 | 600,000.00 |